Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more
Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Liabilities
Latest total liabilities as of September 2025: Skr11.18 Million SEK
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has total liabilities worth Skr11.18 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scandinavian ChemoTech AB Series B - Total Liabilities Trend (2014–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Scandinavian ChemoTech AB Series B Competitors by Total Liabilities
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DS Sigma Holdings Berhad
KLSE:0269
|
Malaysia | RM14.35 Million |
|
OneMeta AI
OTCQB:ONEI
|
USA | $4.31 Million |
|
Agereh Technologies Inc
V:AUTO
|
Canada | CA$7.63 Million |
|
ANAX Metals Ltd
AU:ANX
|
Australia | AU$23.32 Million |
|
Mannatech Incorporated
NASDAQ:MTEX
|
USA | $26.97 Million |
|
Ni Hsin Resources Bhd
KLSE:7215
|
Malaysia | RM36.06 Million |
|
DeepSpatial Inc.
PINK:DSAIF
|
USA | $990.32K |
|
ARB IOT Group Limited Ordinary Shares
NASDAQ:ARBB
|
USA | $68.73 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Scandinavian ChemoTech AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scandinavian ChemoTech AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scandinavian ChemoTech AB Series B (2014–2024)
The table below shows the annual total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr7.40 Million | +92.81% |
| 2023-12-31 | Skr3.84 Million | -50.21% |
| 2022-12-31 | Skr7.71 Million | +307.24% |
| 2021-12-31 | Skr1.89 Million | -71.98% |
| 2020-12-31 | Skr6.75 Million | -12.95% |
| 2019-12-31 | Skr7.76 Million | +235.50% |
| 2018-12-31 | Skr2.31 Million | -9.52% |
| 2017-12-31 | Skr2.56 Million | +13.94% |
| 2016-12-31 | Skr2.24 Million | -61.21% |
| 2015-12-31 | Skr5.78 Million | +29367.34% |
| 2014-12-31 | Skr19.63K | -- |